Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes

Pharmacogenetics: Sequencing finds DNA variants affecting chemoprevention response DNA sequencing has revealed genetic variants that explain inherited variation in responses to preventative drug therapy for breast cancer. Richard Weinshilboum from the Mayo Clinic in Rochester, Minnesota, USA, and co...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Duan Liu, Ming-Fen Ho, Daniel J. Schaid, Steven E. Scherer, Krishna Kalari, Mohan Liu, Joanna Biernacka, Vivien Yee, Jared Evans, Erin Carlson, Matthew P. Goetz, Michiaki Kubo, D. Lawrence Wickerham, Liewei Wang, James N. Ingle, Richard M. Weinshilboum
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/56c8ccff590441f0a7e69f6365d4c7bb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:56c8ccff590441f0a7e69f6365d4c7bb
record_format	dspace
spelling	oai:doaj.org-article:56c8ccff590441f0a7e69f6365d4c7bb2021-12-02T11:51:07ZBreast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes10.1038/s41523-017-0036-42374-4677https://doaj.org/article/56c8ccff590441f0a7e69f6365d4c7bb2017-08-01T00:00:00Zhttps://doi.org/10.1038/s41523-017-0036-4https://doaj.org/toc/2374-4677Pharmacogenetics: Sequencing finds DNA variants affecting chemoprevention response DNA sequencing has revealed genetic variants that explain inherited variation in responses to preventative drug therapy for breast cancer. Richard Weinshilboum from the Mayo Clinic in Rochester, Minnesota, USA, and colleagues previously showed that genetic variations in or near two genes—ZNF423 and CTSO—affected how well the drugs tamoxifen and raloxifene reduced the rate of breast cancer occurrence. Building on that finding, Weinshilboum’s team has now sequenced these two genes in 199 patients who developed breast cancer during chemopreventative drug therapy and 201 patients who did not. They identified around 4000 single-nucleotide polymorphisms across each gene, 21 of which were close to estrogen response element (ERE) motifs to which ERα binds. Functional studies pointed to molecular ways in which some of these gene variants alter drug activity.Duan LiuMing-Fen HoDaniel J. SchaidSteven E. SchererKrishna KalariMohan LiuJoanna BiernackaVivien YeeJared EvansErin CarlsonMatthew P. GoetzMichiaki KuboD. Lawrence WickerhamLiewei WangJames N. IngleRichard M. WeinshilboumNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 3, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Duan Liu Ming-Fen Ho Daniel J. Schaid Steven E. Scherer Krishna Kalari Mohan Liu Joanna Biernacka Vivien Yee Jared Evans Erin Carlson Matthew P. Goetz Michiaki Kubo D. Lawrence Wickerham Liewei Wang James N. Ingle Richard M. Weinshilboum Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes
description	Pharmacogenetics: Sequencing finds DNA variants affecting chemoprevention response DNA sequencing has revealed genetic variants that explain inherited variation in responses to preventative drug therapy for breast cancer. Richard Weinshilboum from the Mayo Clinic in Rochester, Minnesota, USA, and colleagues previously showed that genetic variations in or near two genes—ZNF423 and CTSO—affected how well the drugs tamoxifen and raloxifene reduced the rate of breast cancer occurrence. Building on that finding, Weinshilboum’s team has now sequenced these two genes in 199 patients who developed breast cancer during chemopreventative drug therapy and 201 patients who did not. They identified around 4000 single-nucleotide polymorphisms across each gene, 21 of which were close to estrogen response element (ERE) motifs to which ERα binds. Functional studies pointed to molecular ways in which some of these gene variants alter drug activity.
format	article
author	Duan Liu Ming-Fen Ho Daniel J. Schaid Steven E. Scherer Krishna Kalari Mohan Liu Joanna Biernacka Vivien Yee Jared Evans Erin Carlson Matthew P. Goetz Michiaki Kubo D. Lawrence Wickerham Liewei Wang James N. Ingle Richard M. Weinshilboum
author_facet	Duan Liu Ming-Fen Ho Daniel J. Schaid Steven E. Scherer Krishna Kalari Mohan Liu Joanna Biernacka Vivien Yee Jared Evans Erin Carlson Matthew P. Goetz Michiaki Kubo D. Lawrence Wickerham Liewei Wang James N. Ingle Richard M. Weinshilboum
author_sort	Duan Liu
title	Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes
title_short	Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes
title_full	Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes
title_fullStr	Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes
title_full_unstemmed	Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes
title_sort	breast cancer chemoprevention pharmacogenomics: deep sequencing and functional genomics of the znf423 and ctso genes
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/56c8ccff590441f0a7e69f6365d4c7bb
work_keys_str_mv	AT duanliu breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT mingfenho breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT danieljschaid breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT stevenescherer breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT krishnakalari breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT mohanliu breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT joannabiernacka breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT vivienyee breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT jaredevans breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT erincarlson breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT matthewpgoetz breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT michiakikubo breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT dlawrencewickerham breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT lieweiwang breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT jamesningle breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes AT richardmweinshilboum breastcancerchemopreventionpharmacogenomicsdeepsequencingandfunctionalgenomicsoftheznf423andctsogenes
_version_	1718395163929214976

Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes

Ejemplares similares